breast-cancer

Paclitaxel and cisplatin are the worst offenders for disrupting the gut-brain axis in breast cancer patients.

Systematic comparison of four breast cancer chemotherapy regimens in female mice found paclitaxel caused the most prolonged central pro-inflammatory signaling and cisplatin caused the most sustained gut microbiome disruption. Cyclophosphamide and doxorubicin had more modest effects on the gut-brain…

Paclitaxel and cisplatin are the worst offenders for disrupting the gut-brain axis in breast cancer patients.

Key Findings

Paclitaxel caused most prolonged central pro-inflammatory signaling
Cisplatin produced most sustained gut microbiome disruption
Cyclophosphamide and doxorubicin had modest gut-brain axis effects
50-80% of breast cancer patients on chemotherapy suffer GI side effects
Gut microbiome is a therapeutic target for side effect reduction

Implications

Gut-targeted interventions benefit most from patients receiving paclitaxel or cisplatin. Future trials should stratify by chemotherapy regimen.

Caveats

Preclinical mouse model; abstract-only. Drug doses may differ from clinical practice. Extrapolation to humans requires clinical validation.

Source: Gut microbes — 2026-12-31

Landmark DCIS trial, CRC microbiome & AML combos

Two themes cut across this week’s 236 posts. The first is de-escalation: researchers are building rigorous evidence that patients can safely do less — skip lymph node surgery, forgo radiotherapy, watch pre-invasive lesions instead of cutting them out. The landmark result here is a randomized trial confirming that active surveillance

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.

Paclitaxel and cisplatin are the worst offenders for disrupting the gut-brain axis in breast cancer patients.

Key Findings

Implications

Caveats

Read more

Landmark DCIS trial, CRC microbiome & AML combos

Colorectal Cancer Microbiome Discovery Platform

GBM Tumor Microenvironment Drug Target Atlas

BET Inhibitor Target Selectivity Database